305 related articles for article (PubMed ID: 32945494)
1. Overexpression of novel long intergenic non‑coding RNA LINC02454 is associated with a poor prognosis in papillary thyroid cancer.
Tan J; Liu L; Zuo Z; Song B; Cai T; Ding D; Lu Y; Ye X
Oncol Rep; 2020 Oct; 44(4):1489-1501. PubMed ID: 32945494
[TBL] [Abstract][Full Text] [Related]
2. lncRNA DUXAP8 inhibits papillary thyroid carcinoma cell apoptosis via sponging the miR‑20b‑5p/SOS1 axis.
Pang R; Yang S
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760128
[TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA HIT000218960 promotes papillary thyroid cancer oncogenesis and tumor progression by upregulating the expression of high mobility group AT-hook 2 (HMGA2) gene.
Li T; Yang XD; Ye CX; Shen ZL; Yang Y; Wang B; Guo P; Gao ZD; Ye YJ; Jiang KW; Wang S
Cell Cycle; 2017 Jan; 16(2):224-231. PubMed ID: 27929737
[TBL] [Abstract][Full Text] [Related]
4. The lncRNA UNC5B-AS1 promotes proliferation, migration, and invasion in papillary thyroid cancer cell lines.
Wang Y; Bhandari A; Niu J; Yang F; Xia E; Yao Z; Jin Y; Zheng Z; Lv S; Wang O
Hum Cell; 2019 Jul; 32(3):334-342. PubMed ID: 30805847
[TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA ABHD11-AS1 functions as a competing endogenous RNA to regulate papillary thyroid cancer progression by miR-199a-5p/SLC1A5 axis.
Zhuang X; Tong H; Ding Y; Wu L; Cai J; Si Y; Zhang H; Shen M
Cell Death Dis; 2019 Aug; 10(8):620. PubMed ID: 31409775
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA SNHG22 increases ZEB1 expression via competitive binding with microRNA-429 to promote the malignant development of papillary thyroid cancer.
Gao H; Sun X; Wang H; Zheng Y
Cell Cycle; 2020 May; 19(10):1186-1199. PubMed ID: 32306838
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA CASC9 promotes the proliferation and metastasis of papillary thyroid cancer via sponging miR-488-3p.
Chen Y; Li Y; Gao H
Cancer Med; 2020 Mar; 9(5):1830-1841. PubMed ID: 31943867
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of long noncoding RNA interactions reveals the potential role in progression of human papillary thyroid cancer.
You X; Zhao Y; Sui J; Shi X; Sun Y; Xu J; Liang G; Xu Q; Yao Y
Cancer Med; 2018 Nov; 7(11):5394-5410. PubMed ID: 30318850
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA TTN-AS1 facilitates tumorigenesis of papillary thyroid cancer through modulating the miR-153-3p/ZNRF2 axis.
Cui Z; Luo Z; Lin Z; Shi L; Hong Y; Yan C
J Gene Med; 2019 May; 21(5):e3083. PubMed ID: 30811764
[TBL] [Abstract][Full Text] [Related]
10. Role of differentially expressed genes and long non-coding RNAs in papillary thyroid carcinoma diagnosis, progression, and prognosis.
Cai WY; Chen X; Chen LP; Li Q; Du XJ; Zhou YY
J Cell Biochem; 2018 Nov; 119(10):8249-8259. PubMed ID: 29968931
[TBL] [Abstract][Full Text] [Related]
11. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
12. LncRNA ENST00000539653 acts as an oncogenic factor via MAPK signalling in papillary thyroid cancer.
Song B; Li R; Zuo Z; Tan J; Liu L; Ding D; Lu Y; Hou D
BMC Cancer; 2019 Apr; 19(1):297. PubMed ID: 30940124
[TBL] [Abstract][Full Text] [Related]
13. A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3.
Feng J; Zhou Q; Yi H; Ma S; Li D; Xu Y; Wang J; Yin S
Cell Death Dis; 2019 Jun; 10(6):433. PubMed ID: 31160577
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of serum lncRNA-ABHD11-AS1 as poor prognosis of patients with papillary thyroid carcinoma.
Hou S; Zhuang YY; Lin QY; Chen Z; Zhao HG; Zhang L; Lin CH
Exp Mol Pathol; 2021 Aug; 121():104658. PubMed ID: 34102210
[TBL] [Abstract][Full Text] [Related]
15. Myocardial infarction associated transcript (MIAT) promotes papillary thyroid cancer progression via sponging miR-212.
Wang R; Zhao L; Ji L; Bai L; Wen Q
Biomed Pharmacother; 2019 Oct; 118():109298. PubMed ID: 31404776
[TBL] [Abstract][Full Text] [Related]
16. Growth-associated protein 43 promotes thyroid cancer cell lines progression via epithelial-mesenchymal transition.
Zheng C; Quan RD; Wu CY; Hu J; Lin BY; Dong XB; Xia EJ; Bhandari A; Zhang XH; Wang OC
J Cell Mol Med; 2019 Dec; 23(12):7974-7984. PubMed ID: 31568662
[TBL] [Abstract][Full Text] [Related]
17. PDZK1 Interacting Protein 1 Promotes the Progression of Papillary Thyroid Cancer.
Wang K; Liu S; Tian Y; Liu C; Gui Z; Yu T; Zhang L
J Clin Endocrinol Metab; 2022 Aug; 107(9):2449-2461. PubMed ID: 35727731
[TBL] [Abstract][Full Text] [Related]
18. BGL3 inhibits papillary thyroid carcinoma progression via regulating PTEN stability.
Zhao M; Yang F; Sang C; Yan C; Wang Z
J Endocrinol Invest; 2021 Oct; 44(10):2165-2174. PubMed ID: 33543443
[TBL] [Abstract][Full Text] [Related]
19. HOXD-AS1 is a predictor of clinical progression and functions as an oncogenic lncRNAs in papillary thyroid cancer.
Xu K; Feng Y
J Cell Biochem; 2019 Apr; 120(4):5326-5332. PubMed ID: 30317670
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of long non-coding RNA LINC00982 suppresses cell proliferation and tumor growth of papillary thyroid carcinoma through PI3K-ATK signaling pathway.
Xu D; Yu J; Zhuang S; Zhang S; Hong Z; Yuan C
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31262968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
